Evidence map›Paper›PMID 34104609›Full record

ArticleCureus2021

Comparison of Hepatocellular Carcinoma in Hispanic and Non-Hispanic Patients.

Joseph Asemota, Olubunmi Oladunjoye, Atinuke Babalola, Ugonna Nwosu, Po-Hong S Liu, Adeolu O Oladunjoye, Nelsy Castro-Webb, Rebecca A Miksad

Open access · diamondAbstract read
In one paragraph

Article in Cureus, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 2 countries.

Joseph AsemotaInternal Medicine, Howard University Hospital, Washington DC, USA.
Olubunmi OladunjoyeInternal Medicine, Tower Health-Reading Hospital, West Reading, USA.
Atinuke BabalolaHematology/Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, USA.
Ugonna NwosuHematology/Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, USA.
Po-Hong S LiuInternal Medicine, UT Southwestern Medical Center, Dallas, USA.
Adeolu O OladunjoyeCritical Care Medicine, Boston Children's Hospital, Boston, USA.
Nelsy Castro-WebbEpidemiology and Public Health, Boston University School of Medicine, Boston, USA.
Rebecca A MiksadMedicine, Boston University School of Medicine, Boston, USA.
Beth Israel Deaconess Medical Center · USHarvard University · USBoston Children's Hospital · USBoston University · USReading Hospital · USSouthwestern Medical Center

Funding

UT GASTROENTEROLOGY/HEPATOLOGY RESEARCH TRAINING PROGRAMT32DK007745 · NIDDK · UT SOUTHWESTERN MEDICAL CENTER · PI Rodney E Infante · 1997 to 2026
$6.8M
NIDDK NIH HHS T32 DK007745
6 · The paper itself

Abstract

backgroundHepatocellular carcinoma (HCC) is the fastest growing cancer in the United States. Studies have shown that compared to Blacks and non-Hispanic Whites, Hispanics have a higher HCC incidence and mortality rate. Most studies investigating HCC in Hispanics have been conducted utilizing data largely from the Western and Southern United States. These findings may, however, not be highly representative of Hispanics in the Northeast, given the nonhomogenous distribution and diversity of Hispanics across the United States.

methodsSome 148 HCC patients diagnosed between 1996 and 2012 were identified from a tertiary center in the northeastern United States. Hispanic patients were randomly matched to non-Hispanic White patients by year of diagnosis. Patient characteristics, HCC risk factors, treatment, and outcome were recorded. A Kaplan-Meier (KM) plot with log-rank tests was used for survival analysis.

resultsCompared to non-Hispanic White patients (n=89), Hispanic HCC patients (n=59) were more likely to have chronic hepatitis C infection (69.5% vs. 38.2%, p < 0.01), alcoholic liver disease (37.3% vs. 21.4%, p = 0.04) and were less likely to have chronic hepatitis B infection (6.8% vs. 24.7%, p = 0.01), and private insurance (37.3% vs. 57.3%, p = 0.02). Hispanics were more likely to be diagnosed with an earlier stage disease (Barcelona Clinic Liver Cancer, BCLC stages A and B) compared to non-Hispanic patients (71.7% vs. 36.8%, p < 0.01) and were more likely to receive locoregional treatment. Although Hispanics trended towards improved overall survival, this finding did not hold when stratified by the BCLC stage.

conclusionRisk factors for HCC in the northeastern Hispanic population are like those found among Hispanics in other US regions. Other research suggests Hispanics are at increased risk for hepatic injury and HCC. However, HCC in this northeastern Hispanic population appears to be less aggressive (earlier stage and trend towards better overall survival) than non-Hispanics. Further research may be needed to identify potential differences by ethnic group for HCC risk factors, presentation, and outcomes.

Indexed as

alcoholic liver diseasehepatitis b infectionhepatitis c (hcv) infectionhepatocellular carcinomahispanicsliver cirrhosisnon-hispanic whitesnortheast united statesoutcome disparitiesrisk factors

Identifiers

PMID34104609
PMCPMC8180179
OpenAlexW3161836195

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.